

Patent Claims

1. Pharmaceutical formulation comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance.
2. Pharmaceutical formulation according to claim 1 comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance, wherein the formulation is in the form of a tablet with a content of at least one flow regulator.
3. Pharmaceutical formulation according to claim 1 comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance, wherein the formulation is in the form of a filling for capsules.
4. Pharmaceutical formulation according to claim 1 comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance, wherein the formulation is in the form of a dragée, effervescent tablet, suppository or granulate.
5. Formulation according to at least one of the preceding claims comprising flutamide of a particle size such as is formed in the synthesis process with subsequent purification step(s).
6. Formulation according to claim 5 comprising flutamide of a particle size such as is formed in the synthesis process with recrystallisation as a subsequent purification step.
7. Formulation according to at least one of the preceding claims comprising flutamide of a mean particle size greater than the mean particle size of flutamide that, with an initial particle size of from 5 to 240 µm, has been subjected to a milling operation.
8. Formulation according to at least one of claims 1 to 7 comprising flutamide in which the size of 50 % of the flutamide particles (X50 value) is greater than 20 µm.
9. Formulation according to claim 8 comprising flutamide in which the size of 50 % of the flutamide particles (X50 value) is greater than 26 µm.

10. Formulation according to at least one of claims 1 to 7 comprising flutamide in which the size of 90 % of the flutamide particles (X90 value) is greater than 60 μm .
11. Formulation according to claim 10 comprising flutamide in which the size of 90 % of the flutamide particles (X90 value) is greater than 130 μm .
12. Formulation according to at least one of the preceding claims comprising flutamide of a specific surface area of less than 2.50 m^2/cm^3 .
13. Formulation according to claim 12 comprising flutamide of a specific surface area of less than 1.50 m^2/cm^3 .
14. Formulation according to claim 13 comprising flutamide of a specific surface area of less than 0.35 m^2/cm^3 .
15. Formulation according to at least one of the preceding claims comprising flutamide in the form of the free acid amide and/or of a pharmaceutically acceptable solvate.
16. Formulation according to at least one of the preceding claims comprising at least one surface-active substance selected from the group formed by
 - anionic compounds,
 - cationic compounds and
 - non-ionic surfactants.
17. Formulation according to claim 16 comprising sodium dodecylsulphate as surface-active substance.
18. Formulation according to at least one of the preceding claims with a ratio by weight of flutamide : surface-active substance(s) of from 5 : 1 to 30 : 1.

19. Formulation according to claim 18 with a ratio by weight of flutamide : surface-active substance(s) of from 5 : 1 to 20 : 1.
20. Formulation according to claim 19 with a ratio by weight of flutamide : surface-active substance(s) of from 10 : 1 to 15 : 1.
21. Formulation according to at least one of the preceding claims in the form of an unshaped mixture or in the form of an article that has been subjected to shaping.
22. Formulation according to claim 21 with a content of from 50 to 2000 mg of flutamide.
23. Formulation according to claim 22 with a content of from 50 to 500 mg of flutamide.
24. Formulation according to claim 23 with a content of from 100 to 200 mg of flutamide.
25. Formulation according to at least one of the preceding claims with a content of at least one excipient from the group formed by inorganic fillers, organic fillers, binders, glidants, lubricants, flow regulators and/or disintegrants.
26. Formulation according to at least one of the preceding claims with a content of at least one further pharmaceutical active ingredient besides flutamide.
27. Process for the preparation of a pharmaceutical formulation according to at least one of claims 1 and 5 to 26 comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance, in which the flutamide is subjected to an intensive mixing process with the at least one surface-active substance.
28. Process for the preparation of a pharmaceutical formulation according to claim 2, 3 or 4 comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance, in which the flutamide is subjected to an intensive mixing process with the at least one surface-active substance, and the mixture obtained is further processed to form a formulation according claim 2, 3 or 4.

29. Process according to claim 27 or 28 in which mixing is carried out at a temperature of from 0 to 40°C.

30. Process according to claim 29 in which mixing is carried out at room temperature.

31. Process according to at least one of claims 27 to 30 in which one or more excipients are admixed using a forced-action mixer or using a free-fall mixer.

32. Process according to at least one of claims 27 to 31 in which one or more further pharmaceutical active ingredients, which are not flutamide, are admixed using a forced-action mixer or a free-fall mixer.

33. Process according to at least one of claims 27 and 29 to 32 in which the mixture obtained is further processed to form tablets, capsules, dragées, effervescent tablets, suppositories or a granulate.

34. Process according to claim 28 and/or according to claim 33 in which the mixture obtained is subject to direct tableting.

35. Process according to claim 28 and/or according to claim 33 in which the granulate is further processed to form tablets.

36. Pharmaceutical formulation comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance, producible in accordance with a process according to at least one of claims 27 to 35.